Previous Close | 1.8000 |
Open | 1.8150 |
Bid | 1.9400 x 3100 |
Ask | 1.9900 x 900 |
Day's Range | 1.7600 - 2.0050 |
52 Week Range | 1.6500 - 16.0000 |
Volume | |
Avg. Volume | 49,007 |
Market Cap | 3.834M |
Beta (5Y Monthly) | 1.13 |
PE Ratio (TTM) | 0.01 |
EPS (TTM) | 141.0400 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 250.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AGRX
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY. Details on the Company presentation are as follows: Event: H.C. Wainwright 25th Annual Global Investment Conference Date: Wednesday, Sep
On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses.
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript August 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-3.1, expectations were $-3.48. Operator: Good morning, and welcome to the Agile Therapeutics Second Quarter of 2023 Financial Results Conference Call. Please note today’s event is being recorded. I would now like to turn […]